secukinumab,adalimumab
novartis,abbvie
['axspa', 'surpass']
d vd heijde hot session on #axspa 1 quality standards for early referral, dx, mx, easy access for flares
2 asdas &gt; basdai 3 nsaid still 1st line, prolonged use 4 choose bdmard acc to extra-msk s/s
5 surpass study ada biosimilar = sec for radiographic prog #eular2023 
Rheumatologist @NUSingapore @AIIMS_NewDelhi || Follow for #Rheum nuggets 🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own 🇸🇬🇮🇳